Vertically integrated, medical device contract manufacturing organization serving the medical device, diagnostics and drug delivery markets Cadence, Inc. announced on Thursday that it has named Bob White as a new director.
White brings more than 25 years of leadership experience in operational excellence, innovation, and strategic growth. White previously held senior roles at Medtronic, GE Healthcare and IBM, demonstrating expertise in managing global operations. As executive vice president and group president at Medtronic, he led 25,000 employees across 70 countries, overseeing five global businesses and driving above-market growth. White also executed seven acquisitions, a joint venture and a multi-billion-dollar divestiture. Currently, he serves as an Independent Director for Smith & Nephew and formerly held board positions at Mozarc Medical and CARE Hospitals. His background in medical device manufacturing and strategic insight will enhance Cadence's leadership team.
Matt Jennings, Cadence's chairman of the board, said, 'Bob will be an excellent addition to our board. His impressive track record in global business leadership and his commitment to innovation and growth will be instrumental as Cadence continues to advance its strategic goals and drive success, and he will be valuable to both the Board and Cadence's leadership team with their go-to market approach.'
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits
Samsung Biologics honoured at 2026 CDMO Leadership Awards
Frost & Sullivan names Abzena a market-leading ADC CDMO
Vulcan Two signs five-year ERP licence agreement to support ePharmacy expansion
SportsMed Physical Therapy named Physical Therapy Company of the Year
Ensorcell adds new senior leadership team members
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study